X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

WHO Body Recommends Vaccines To Be Updated For Variants

Content Team by Content Team
13th January 2022
in News
The UK begins the biggest ever immunization program

The technical body of the World Health Organization has confirmed that the COVID-19 vaccines, which the world is using currently, may have to be reworked to ensure their effectiveness against not only Omicron but future variants as well that may arise from nowhere. The technical group which is made up of independent experts, has confirmed that they would prefer a composition change in the vaccines to fight out the variants that are in line. All in all the current dosage of the range of brands of vaccinations that are being used for fighting out Coronavirus infection, according to these experts, must undergo an overhaul.

The technical body, in a statement issued from their end, has said that the vaccine composition may as well have to be updated in order to ensure that they continue to consistently provide the WHO-recommended levels of high protection against the infection as well as variants of concern that include delta, omicron, and other future variants.

The statement added that these vaccinations need to give out long-lasting responses, are strong and wide so as to eradicate the possibility of booster doses. The experts are of an opinion that the strategy based on repeat vaccination or booster, as we call them, may not be as suitable and sustainable as it looks.

That said, the statement hasn’t spilled any beans on advocacy of Omicron-specific vaccines, at least at this stage, and throws light on more research and data sharing. As per the statement, an updated vaccine specifically made to keep a check on dominant variants all at once must be the need of the hour.

As per the reports, the makers are already in the process of developing the generation next vaccines for Omicron and alike variants which are highly contagious. Albert Bourla, Chief Executive of Pfizer, has opined that a redesigned vaccination that focuses on Omicron in all likelihood will be needed, and their company may have one furnished by March. Moderna, on the other hand, is already working on a vaccine candidate, but that will not be available before two months. WHO has time and again said that the composition of vaccines will require global coordination, and it will be unfair to let the manufacturers decide alone and take the burden.

Previous Post

To Scale Up Quantum Drug Discovery, Oxford Joins Consortium

Next Post

Cystic Fibrosis Treatment for 6-11 Years Old Gets A Nod

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
Cystic Fibrosis Treatment for 6-11 Years Old Gets A Nod

Cystic Fibrosis Treatment for 6-11 Years Old Gets A Nod

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In